AGIOS PHARMACEUTICALS INC (AGIO)
Health Care · Biotechnology · NASDAQ
Agios Pharmaceuticals is a rare disease-focused biopharmaceutical company advancing a pipeline of novel hematology and genetic disorder therapies, anchored by its pyruvate kinase activator, mitapivat.
What AGIOS PHARMACEUTICALS INC does
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases, particularly hematologic disorders. Its lead product, mitapivat, is a pyruvate kinase activator marketed under the brands AQVESME and PYRUKYND for the treatment of hemolytic anemias, including PK deficiency and thalassemia. The company is actively expanding its pipeline with treatments for sickle cell disease, phenylketonuria, polycythemia vera, and immune thrombocytopenia.
Themes: rare diseases, hematology, sickle cell disease, gene regulation / siRNA, autoimmune diseases
Fundamentals
- Price$33.09 as of 2026-08-21 close
- Market cap$2.0B as of 2026-08-21
- 1-year return-13.4% 2025-08-21 close $38.20 → 2026-08-21 close $33.09
- P/En/a negative earnings
- Net margin-418.2% as of 2026-08-24
- Gross margin+92.0% as of 2026-08-24
- ROE-35.7% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+140.6% as of 2026-08-24
- Revenue CAGR (3y)+56.0% SEC XBRL
- Beta0.64 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How AGIO compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
AGIO is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
45.8 #1071 of 1,704 scored · #190 of 240 in Health Care
Catalysts 62nd: open-market insider buys in 90 days 36, the analyst consensus rating is unchanged since the prior reading; momentum 55th: over the past 3 months this stock beat the market by 15.1 percentage points; weakest is volume and participation 10th: it gapped 10.7% below the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How AGIOS PHARMACEUTICALS INC looks technically
AGIOS PHARMACEUTICALS INC (AGIO) is trading 6.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 28 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive). It made a new 20-day low about 16 trading days ago. It is 28.0% below its highest point of the past year. Trading volume is unusually light — only about 50% of its 30-day average.
Trend
9
| Distance from the 200-day | it is trading 6.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +6.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $35.56 | $35.56 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.06 | $31.06 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 29.15. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 28 trading days ago — a "golden cross", a bullish long-term signal | 28 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 6.5% above | +6.5% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 17, below the 25 that marks a real trend) | 17.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.7 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($30.23 to $35.98) — its "stochastic" reading is 50 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 49.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $45.99 | $45.99 |
|---|---|---|
| From the 52-week high | it is 28.0% below its 52-week high (its highest price of the past year) | -28.1% |
| Above the 52-week low | it is 48.8% above its 52-week low (its lowest price of the past year) | +48.8% |
| Below the 52-week high | it is 28.0% below its highest point of the past year | 28.1% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $138.85 (set on 2015-01-15) | $138.85 |
| Given back of the 52-week move | over the past year its closes ranged ($22.34 to $45.49), and it has recovered around half of its fall from last year’s high — 46% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $36.65 to $37.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 1 day, so it is a narrow thing to be measuring a retracement against. | 46.4% |
| From the all-time high | it is 76.2% below its all-time high | -76.2% |
| Nearest price level | it is trading 1.3% above a support level at $32.65 — a price it turned at four times since 2025-03-21, most recently on 2026-04-10. Since 2024-08-21 it has 10 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $15.77 (set on 2013-11-18) | $15.77 |
| Above the all-time low | it is 109.8% above its all-time low | +109.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 39th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.61 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.61 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $29.88 and $36.64 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $29.88 – $33.26 – $36.64 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 1.3 daily ranges above its 200-day average price (6.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.3 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 50% of its 30-day average | 0.50× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 at essentially the same price it closed at the session before — no meaningful overnight gap | -0.0% |
|---|---|---|
| Open gap | it gapped 10.7% below the previous close 23 sessions ago and has not traded back through the level it left behind at 40.06 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -10.7% |
| Gap filled | a 2.9% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -5.78% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 13.8 percentage points (the stock lost 11.4% while the market gained 2.3%) | -13.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.8 percentage points (the stock gained 14.9% while the market gained 3.1%) | +11.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 2.1 percentage points (the stock gained 13.1% while the market gained 11.1%) | +2.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 33.9 percentage points (the stock lost 13.4% while the market gained 20.5%) | -33.9% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.1% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -5.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $31.25 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | +5.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $32.69 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +1.2% |
Price levels it has turned at before
AGIO last closed at $33.09 on 2026-08-21. Since 2024-08-21 it has turned at 10 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $32.65 | Support | 1.3% below the last close | turned there four times · 2025-03-21 to 2026-04-10 |
| $31.52 | Support | 4.8% below the last close | turned there four times · 2025-01-02 to 2025-05-02 |
| $30.73 | Support | 7.1% below the last close | turned there three times · 2025-03-17 to 2026-05-28 |
| $36.13 | Resistance | 9.2% above the last close | turned there 7 times · 2025-01-08 to 2026-04-17 |
| $39.83 | Resistance | 20.4% above the last close | turned there twice · 2024-10-07 to 2025-10-14 |
| $43.28 | Resistance | 30.8% above the last close | turned there four times · 2024-09-06 to 2025-10-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $29.15.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $46.78 and $57.68 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $29.15.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · trendless / choppy (low ADX) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.60 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$45.75 range $32.00 – $73.00; median $42.50
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AGIO
- Consensus EPS estimate-$1.19 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the commercial success of mitapivat and its ability to secure additional regulatory approvals, particularly in sickle cell disease.","Inherent risks of clinical trial failures, regulatory delays, or failure to demonstrate clinical benefit for new indications.","Substantial history of losses and potential need for additional capital to fund research, development, and commercial operations."]
What changed in the latest 10-Q
AI-assisted comparison of AGIO's 10-Q filed 2026-04-29 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- AQVESME™ brand name approval in United States for thalassemia treatment (newer filing, 2026-04-29)
- Mitapivat approval in Saudi Arabia and United Arab Emirates under PYRUKYND® brand (newer filing, 2026-04-29)
- First quarter 2026 presentation of RISE UP study data and phase 2/3 results for SCD (newer filing, 2026-04-29)
- FDA pre-supplemental New Drug Application meeting with FDA for SCD indication (newer filing, 2026-04-29)
- Plan to submit supplemental New Drug Application for mitapivat in SCD in second quarter 2026 (newer filing, 2026-04-29)
- Proposal for confirmatory clinical trial with different primary endpoint for SCD accelerated approval (newer filing, 2026-04-29)
- Details of Royalty Pharma acquisition with 12% earn-out on excess U.S. net sales above $1.0 billion and Agio's retained 3% earn-out (newer filing, 2026-04-29)
- Removed:
- Supplemental new drug application sNDA filing description to FDA for thalassemia (older filing, 2025-10-30)
- FDA PDUFA goal date of September 7, 2025 and extension to December 7, 2025 (older filing, 2025-10-30)
- REMS submission details for hepatocellular injury risk mitigation (older filing, 2025-10-30)
- Saudi Food and Drug Authority approval announcement in August 2025 (older filing, 2025-10-30)
- Reference to Alnylam License Agreement section with milestone payment details (older filing, 2025-10-30)
- Specific $10.0 million regulatory milestone payment to Alnylam achieved in nine months ended September 30, 2025 (older filing, 2025-10-30)
- Reworded:
- Reference period changed from September 30, 2025 to March 31, 2026 (newer filing, 2026-04-29)
- Reference to 10-K filing date changed from February 13, 2025 to February 12, 2026 (newer filing, 2026-04-29)
- Reference to 10-K year changed from December 31, 2024 to December 31, 2025 (newer filing, 2026-04-29)
- Overview company description changed from 'We champion an inclusive culture' language to 'Fueled by connections, we build trusted partnerships' language (newer filing, 2026-04-29)
- Mitapivat product description reordered to list AQVESME™ first before detailing approvals (newer filing, 2026-04-29)
- SCD evaluation language changed from 'currently evaluating PYRUKYND®' to specific study data presentation and submission timeline (newer filing, 2026-04-29)
- Expected regulatory decision timeline for EMA changed from 'early 2026' to 'first half of 2026' (newer filing, 2026-04-29)
- Notes:
- Older filing text appears truncated at end of MD&A section, limiting full comparison of Financial Operations Overview section
- Alnylam License Agreement section appears in older filing but is absent from provided newer filing excerpt, though this may be due to reorganization rather than removal
Risk Factors
- Added:
- AQVESME™ product and commercialization discussed throughout the risk factors section (filed 2026-04-29)
- Reference to AQVESME™ commercial launch in United States in late January 2026 (filed 2026-04-29)
- $20.7 million and $8.7 million net product revenues from PYRUKYND® and AQVESME™ for three months ended March 31, 2026 and 2025 (filed 2026-04-29)
- Mention of United Arab Emirates regulatory approval context (filed 2026-04-29)
- REMS requirements specific to AQVESME™ referenced in risk factors (filed 2026-04-29)
- Reference to mitapivat as potential approval for thalassemia in EU and SCD in United States (filed 2026-04-29)
- Removed:
- Detailed regulatory timeline for PYRUKYND® thalassemia indication including December 2024 sNDA submission, PDUFA goal dates, FDA extension, Saudi Food and Drug Authority approval in August 2025, and CHMP positive opinion (filed 2025-10-30)
- $34.1 million and $25.8 million net product revenues from PYRUKYND® for nine months ended September 30, 2025 and 2024 (filed 2025-10-30)
- Specific reference to pending regulatory decisions expected by early 2026 for European Commission review (filed 2025-10-30)
- Language about 'PYRUKYND® (mitapivat) is approved for use by the FDA' for PK deficiency and regulatory approval details (filed 2025-10-30)
- Reference to 'a significantly number of eligible patients with PK deficiency' (filed 2025-10-30)
- Sentence stating 'While we have recently received approval from the Saudi Food and Drug Authority for PYRUKYND®...' (filed 2025-10-30)
- Reworded:
- Header changed from 'If we do not successfully commercialize PYRUKYND® and other products for which we receive approval' to 'If we do not successfully commercialize PYRUKYND®, AQVESME™ and other products for which we receive approval' (filed 2026-04-29)
- Risk factor bullets now reference both 'PYRUKYND® or AQVESME™' instead of only 'PYRUKYND®' throughout the list (filed 2026-04-29)
- Changed 'PYRUKYND® for the treatment of thalassemia or SCD' to 'mitapivat for the treatment of thalassemia in the EU, or SCD' in clinical-stage candidates discussion (filed 2026-04-29)
- Changed from 'including PYRUKYND® and tebapivat' to 'including mitapivat and tebapivat' in description of advanced clinical programs (filed 2026-04-29)
- Removed specific language about 'a commercially viable manufacturing process' (singular) and changed to 'commercially viable manufacturing processes' (plural) to reflect both products (filed 2026-04-29)
- Bullet point changed from 'competing drug products are approved for the same indications as PYRUKYND®' to 'competing drug products are approved for the same indications or in the same jurisdictions as PYRUKYND® or AQVESME™' (filed 2026-04-29)
- REMS language changed from 'the requirements of a REMS make it more difficult' to 'the requirements of the AQVESME™ REMS make it more difficult' (filed 2026-04-29)
- Notes:
- The newer filing appears to be truncated at the end of the provided text, cutting off mid-sentence in a risk factor discussion
- The older filing also appears to be truncated, cutting off at 'We cannot guarantee that any clinical trials'
- Page reference changed from 'page 18' (older filing) to 'page 17' (newer filing), likely due to document length changes
- Comparison reflects only the portions of text provided; full extent of changes in complete documents may differ
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 1 sell ($914400) — 1 selling insider
- Last 90 days0 buys · 2 sells ($1M) — 1 selling insider
- Last 180 days0 buys · 9 sells ($2M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-04. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AGIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 4 matched disclosures for AGIO from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
4 institutional 13F filers reported holding AGIO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 9,898,370
- Reported value $334,747,376
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AGIO had 6,840,722 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AGIO had 11.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 5.14 days to cover at the same settlement.
- Reported short interest (shares) 6,840,722
- Short interest (% of shares outstanding) 11.5%
- Prior settlement (shares) 6,630,197
- Reported change 3.18%
- Days to cover (reported) 5.14
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bluebird Bio (BLUE)
- Vertex Pharmaceuticals (VRTX)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- BioMarin Pharmaceutical (BMRN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AGIO vs…
AGIOS PHARMACEUTICALS INC is found in…
Frequently asked questions
What does AGIOS PHARMACEUTICALS INC (AGIO) do?
Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing medicines for rare genetic diseases, particularly hematologic disorders. Its lead product, mitapivat, is a pyruvate kinase activator marketed under the brands AQVESME and PYRUKYND for the treatment of hemolytic anemias, including PK deficiency and thalassemia.
What sector is AGIOS PHARMACEUTICALS INC (AGIO) in?
AGIOS PHARMACEUTICALS INC (AGIO) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are AGIOS PHARMACEUTICALS INC's (AGIO) competitors?
Notable peers of AGIOS PHARMACEUTICALS INC (AGIO) include Bluebird Bio, Vertex Pharmaceuticals, Bristol Myers Squibb, Novartis and BioMarin Pharmaceutical. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in AGIO?
Yes — we hold 4 matched STOCK Act disclosures for AGIO from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AGIOS PHARMACEUTICALS INC (AGIO) overbought or oversold right now?
AGIOS PHARMACEUTICALS INC (AGIO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AGIO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.